Zevra Therapeutics Inc [ZVRA] stock is trading at $7.99, up 3.50%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZVRA shares have gain 1.40% over the last week, with a monthly amount glided 3.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on October 07, 2024, and set its price target to $20. On September 24, 2024, Maxim Group reiterated its Buy rating and revised its price target to $25 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $17 on September 24, 2024. Maxim Group reiterated its recommendation of a Buy and raised its price target to $18 on April 02, 2024. In a note dated March 17, 2023, Maxim Group initiated an Buy rating and provided a target price of $12 on this stock.
Zevra Therapeutics Inc [ZVRA] stock has fluctuated between $4.20 and $9.76 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Zevra Therapeutics Inc [NASDAQ: ZVRA] shares were valued at $7.99 at the most recent close of the market. An investor can expect a potential return of 162.83% based on the average ZVRA price forecast.
Analyzing the ZVRA fundamentals
Zevra Therapeutics Inc [NASDAQ:ZVRA] reported sales of 24.79M for the trailing twelve months, which represents a growth of 27.63%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -3.48%, Pretax Profit Margin comes in at -3.43%, and Net Profit Margin reading is -3.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -1.6 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.79 points at the first support level, and at 7.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.09, and for the 2nd resistance point, it is at 8.20.
Ratios To Look Out For
For context, Zevra Therapeutics Inc’s Current Ratio is 2.88. In addition, the Quick Ratio stands at 2.88 and the Cash Ratio stands at 1.57. Considering the valuation of this stock, the price to sales ratio is 17.20, the price to book ratio is 6.10.
Transactions by insiders
Recent insider trading involved NEIL F MCFARLANE, Director, that happened on Feb 13 ’25 when 91817.0 shares were purchased. Officer, R. LADUANE CLIFTON completed a deal on Feb 13 ’25 to buy 11000.0 shares. Meanwhile, Officer Timothy Sangiovanni bought 3000.0 shares on Feb 13 ’25.
